Anders Ljungberg

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

Bruce Strober, Craig L. Leonardi, Kim Papp et al. · Journal of the American Academy of Dermatology · 2016 · 130 citations

Pharmacy, Immunology, Pharmacotherapy +17

Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-? therapy

Lotus Mallbris, Anders Ljungberg, Mari‐Anne Hedblad et al. · Journal of the American Academy of Dermatology · 2003 · 90 citations

Medicine, Dermatology, Immunology +12

Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden – a cross-sectional study

Ola Ghatnekar, Anders Ljungberg, Lars-Erik Wirestrand et al. · European Journal of Dermatology · 2012 · 39 citations

Pharmacy, Dermatology, Pharmacoeconomics +13

Methodological aspects on immunohistochemistry in dermatology with special reference to neuronal markers

Anders Ljungberg · The Histochemical Journal · 1993 · 37 citations

Medicine, Dermatology, Pathology +16

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes

L. Puig, Martín Dossenbach, Lovisa Berggren et al. · Acta Dermato Venereologica · 2019 · 36 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17